| 1 |
NCT00475007 |
Completed |
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema |
|
- Device: IBV® Valve System
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Difference between responder rates of the treatment & control groups, responders defined as subjects with clinically meaningful improvements in disease-related health status (SGRQ) & regional lung volume changes as measured by quantitative CT scan.
- The difference between average 6 minute walk test results for treatment & control groups.
|
277 |
All |
40 Years to 74 Years (Adult, Senior) |
NCT00475007 |
CPR-01377 |
IBV®Valve |
September 2007 |
February 2011 |
August 2017 |
May 17, 2007 |
April 17, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Kaiser Permanente Medical Center
Los Angeles, California, United States - University of California Los Angeles (UCLA)
Los Angeles, California, United States - (and 31 more...)
|
| 2 |
NCT00730301 |
Unknown † |
EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema |
- Emphysema
- Chronic Obstructive Pulmonary Disease
|
- Procedure: Bronchoscopic Lung Volume Reduction (BLVR)
|
Interventional |
Phase 4 |
- LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean % change in lung function (FEV1)
- Mean % change in target lobe Residual Volume and Total Lung Capacity. Mean absolute change in dyspnea (mMRC-Score), Quality of life using St. George's Respiratory Questionnaire and SF-36.
|
20 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT00730301 |
EUROPT 07-074-0507 |
EUROPT |
July 2007 |
September 2008 |
|
August 8, 2008 |
August 8, 2008 |
|
- Otto Wagner Hospital
Vienna, Austria - University Antwerp
Antwerp, Belgium - University Brussels
Brussels, Belgium
|
| 3 |
NCT03474471 |
Not yet recruiting
New |
A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema. |
|
- Behavioral: Pulmonary rehabilitation
- Device: EBV treatment
|
Interventional |
Not Applicable |
- University Medical Center Groningen
- Maastricht University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Endurance time
- Pulmonary rehabilitation1
- Pulmonary rehabilitation2
- (and 4 more...)
|
135 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03474471 |
SOLVE |
SOLVE |
June 1, 2018 |
June 1, 2021 |
March 1, 2022 |
March 22, 2018 |
March 26, 2018 |
|
- University Medical Center Groningen
Groningen, Netherlands - Maastricht University Medical Center
Maastricht, Netherlands
|
| 4 |
NCT00129584 |
Completed |
Endobronchial Valve for Emphysema Palliation Trial (VENT) |
- Chronic Obstructive Pulmonary Disease
- Emphysema
|
- Procedure: Emphasys Endobronchial Valve and procedure
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pulmonary function testing at various time points through one year
- Exercise tolerance at various time points through one year
- Major complications at various time points through one year
- (and 2 more...)
|
270 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT00129584 |
630-0001 |
|
January 2004 |
|
|
August 12, 2005 |
August 18, 2009 |
|
|
| 5 |
NCT00137956 |
Terminated |
Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study |
- Emphysema
- Chronic Obstructive Pulmonary Disease
|
- Device: Emphasys Endobronchial Valve (EBV) Device and Procedure
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The cost-effectiveness ratio in the treatment group as compared to the control group at 180 days
- The cost-effectiveness ratio in the treatment group of the study will be compared to established therapies and standards.
|
270 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT00137956 |
630-0005 |
|
December 2004 |
|
|
August 30, 2005 |
August 18, 2009 |
|
|
| 6 |
NCT02059057 |
Active, not recruiting |
LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009) |
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference from Baseline to 12 months in 6 MWT in cross over subjects from CLN0009 study.
|
102 |
All |
36 Years and older (Adult, Senior) |
NCT02059057 |
CLN0016 |
CROSSOVER |
December 2013 |
June 2017 |
June 2021 |
February 11, 2014 |
June 1, 2016 |
|
- University of Alabama Lung Health Center
Birmingham, Alabama, United States - Cedars Sinai Medical Center
Los Angeles, California, United States - El Camino Hospital/Palo Alto Medical Foundation
Mountain View, California, United States - (and 22 more...)
|
| 7 |
NCT00263887 |
Completed
Has Results |
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) |
- Alpha 1-Antitrypsin Deficiency
|
- Drug: Alpha1-Proteinase Inhibitor (Human)
- Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung
- Change in Lung Density at Each Visit as Measured by Computed Tomography
- The Frequency of Exacerbations as Determined by Patient Diary.
- (and 4 more...)
|
77 |
All |
18 Years and older (Adult, Senior) |
NCT00263887 |
100533 |
|
December 2003 |
January 2007 |
January 2007 |
December 9, 2005 |
August 21, 2014 |
August 21, 2014 |
- Gentofte Hospital Department of Respiratory Medicine
Hellerup, Denmark - Department of Pulmonary Medicine, Malmö University Hospital
Malmö, Sweden - Queen Elizabeth Hospital
Birmingham, England, United Kingdom
|
| 8 |
NCT00391612 |
Unknown † |
EASE Trial: Exhale Airway Stents for Emphysema |
|
- Device: Exhale® Drug-Eluting Stent
- Device: Sham control
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Forced Vital Capacity (FVC)
- modified Medical Research Council (mMRC) score (breathlessness)
- Residual Volume/Total Lung Capacity (RV/TLC)
- (and 7 more...)
|
450 |
All |
35 Years and older (Adult, Senior) |
NCT00391612 |
Protocol 30 |
EASE |
May 2006 |
October 2009 |
December 2013 |
October 24, 2006 |
January 12, 2011 |
|
- Pulmonary Associates, PA
Phoenix, Arizona, United States - UCSF-Fresno
Fresno, California, United States - University of Southern California
Los Angeles, California, United States - (and 34 more...)
|
| 9 |
NCT02823223 |
Active, not recruiting |
Endobronchial Valve in Patients With Heterogeneous Emphysema |
- Chronic Obstructive Pulmonary Disease
- Emphysema
|
- Device: Zephyr endobronchial valve placement
|
Interventional |
Not Applicable |
- Chinese PLA General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage change in Forced Expiratory Volume in 1 s (FEV1)
- Comparison of the FEV1 using 15% Percentage change as cut-off for clinically significant change
- Change in Residual Volume (RV)
- (and 7 more...)
|
72 |
All |
35 Years and older (Adult, Senior) |
NCT02823223 |
S2016-026-01 |
|
June 2016 |
December 2017 |
July 2018 |
July 6, 2016 |
July 6, 2016 |
|
- Chinese PLA General Hospital
Beijing, Beijing, China
|
| 10 |
NCT02022683 |
Active, not recruiting |
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV |
- COPD
- Heterogeneous Emphysema
|
- Device: ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in FEV1
- Changes in St George's Respiratory Questionnaire, 6-Min Walk Test, BODE index, mMRC score,
|
97 |
All |
40 Years and older (Adult, Senior) |
NCT02022683 |
630-0015/A |
TRANSFORM |
December 2013 |
December 2016 |
December 2018 |
December 30, 2013 |
April 7, 2017 |
|
- Universiteit Gent
Gent, Belgium - AZ Delta
Menen, Belgium - CHU
Grenoble, France - (and 14 more...)
|
| 11 |
NCT00000606 |
Completed |
National Emphysema Treatment Trial (NETT) |
- Emphysema
- Lung Diseases
- Lung Diseases, Obstructive
- Chronic Obstructive Pulmonary Disease
|
- Procedure: Lung volume reduction surgery
|
Interventional |
Phase 3 |
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
All |
up to 100 Years (Child, Adult, Senior) |
NCT00000606 |
218 |
|
December 1996 |
December 2005 |
December 2005 |
October 28, 1999 |
April 14, 2016 |
|
|
| 12 |
NCT01682018 |
Unknown † |
The Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung |
- Native Lung Overinflation in Patients That Underwent Single Lung Transplantation Due to Emphysema
|
- Device: lung volume reduction using the Zephyr device
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- •Mean % change in lung function (FEV1)
- Mean change in six minutes walk distance
|
15 |
All |
18 Years to 65 Years (Adult) |
NCT01682018 |
RMC126908 |
|
September 2012 |
September 2013 |
September 2013 |
September 10, 2012 |
September 10, 2012 |
|
- Rabin Medical Center
Petah Tikva, Israel
|
| 13 |
NCT01334307 |
Completed |
Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study) |
|
- Device: Lung Volume Reduction Coil (LVRC) (PneumRx)
- Device: Control
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- St. George's Respiratory Questionnaire (SGRQ)
|
47 |
All |
35 Years and older (Adult, Senior) |
NCT01334307 |
CLN0008 |
|
February 2010 |
June 2013 |
September 2013 |
April 13, 2011 |
January 24, 2014 |
|
- Glasgow, United Kingdom
- Chelsea and Westminster Hospital
London, United Kingdom - Manchester, United Kingdom
|
| 14 |
NCT00650559 |
Terminated |
Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema |
|
- Procedure: Chest wall enlargement
|
Interventional |
Not Applicable |
- Katholieke Universiteit Leuven
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement of FEV1
- Improvement of exercise capacity
|
4 |
All |
50 Years to 70 Years (Adult, Senior) |
NCT00650559 |
TE-001
No grants or contracts |
TE |
June 2004 |
December 2006 |
December 2006 |
April 1, 2008 |
April 1, 2008 |
|
- University hospital Leuven
Leuven, Flanders, Belgium
|
| 15 |
NCT01460108 |
Unknown † |
AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation |
- Pulmonary Emphysema
- COPD
- Lung Diseases
|
|
Interventional |
Phase 4 |
- LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Forced Expiratory Volume in one second (FEV1)
- Change in Forced Expiratory Volume in one second (FEV1).
- Change in Forced Vital Capacity (FVC)
- (and 6 more...)
|
10 |
All |
Child, Adult, Senior |
NCT01460108 |
EK_11_027_0311 |
CV+ |
April 2011 |
December 2012 |
June 2013 |
October 26, 2011 |
October 27, 2011 |
|
- Otto-Wagner-Spital
Wien, Austria
|
| 16 |
NCT01902732 |
Unknown † |
Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures |
|
- Device: Implantation of valves (IBV)
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement on pulmonary function
- Assessment of safety and efficacy
|
50 |
All |
Child, Adult, Senior |
NCT01902732 |
Protocol G1.0.- 16.02.2012 |
|
June 2013 |
December 2014 |
|
July 18, 2013 |
July 18, 2013 |
|
- LungenClinic Grosshansdorf
Grosshansdorf, Germany - LungenClinic Grosshansdorf
Großhansdorf, Germany - Thoraxklinik Heidelberg
Heidelberg, Germany - (and 2 more...)
|
| 17 |
NCT00413205 |
Completed |
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) |
|
- Drug: Placebo
- Drug: RAR Gamma
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Post-bronchodilator FEVI
- DLCo, lung densitometry, SGRQ, lung volume, walk test, time to first COPD exacerbation.
- AEs, SAEs, retinoid side effects, lab parameters.
|
491 |
All |
44 Years and older (Adult, Senior) |
NCT00413205 |
NB19751 |
|
January 2007 |
May 2010 |
May 2010 |
December 19, 2006 |
November 2, 2016 |
|
- Birmingham, Alabama, United States
- Los Angeles, California, United States
- San Diego, California, United States
- (and 61 more...)
|
| 18 |
NCT03228121 |
Enrolling by invitation |
Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD |
- COPD
- Emphysema or COPD
- Chronic Bronchitis
|
- Procedure: Treatment Then Placebo
- Procedure: Placebo Then Treatment
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Quality of Life Score
- Change in FEV1
|
100 |
All |
16 Years and older (Child, Adult, Senior) |
NCT03228121 |
LI003 |
|
April 24, 2017 |
May 24, 2018 |
November 24, 2018 |
July 24, 2017 |
July 26, 2017 |
|
- Lung Institute Dallas
Dallas, Texas, United States
|
| 19 |
NCT02630316 |
Recruiting |
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE |
- Pulmonary Hypertension
- Interstitial Lung Disease
- Combined Pulmonary Fibrosis and Emphysema
|
- Drug: Inhaled Treprostinil
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure from Baseline to Week 16
- Change in Peak 6-minute Walk Distance (6MWD) from Baseline to Week 12
- Change in Trough 6-minute Walk Distance (6MWD) from Baseline to Week 15
- Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to Week 16
|
314 |
All |
18 Years and older (Adult, Senior) |
NCT02630316 |
RIN-PH-201 |
|
May 2016 |
December 2018 |
December 2018 |
December 15, 2015 |
March 7, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - IMC-Diagnostic & Medical Clinic
Mobile, Alabama, United States - Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona, United States - (and 108 more...)
|
| 20 |
NCT01528267 |
Completed |
Bronchoscopic Lung Volume Reduction Using Blood |
|
- Other: Autologous blood
- Other: Normal saline
|
Interventional |
Phase 2 |
- Chelsea and Westminster NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Evidence of scarring and volume loss on CT scanning
- To ensure no significant lung function deteriorations at 6 weeks post-procedure
|
10 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01528267 |
08/H0708/100 |
|
November 2009 |
March 2013 |
March 2013 |
February 7, 2012 |
December 20, 2013 |
|
- Chelsea and Westminster NHS Foundation Trust
London, United Kingdom
|
| 21 |
NCT01849159 |
Withdrawn |
Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema |
|
- Biological: Mesenchymal stem cells
- Other: Reference therapy: 400 mL of 0.9% NaCl solution
|
Interventional |
Phase 1
Phase 2 |
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety compared with placebo
- Change from baseline in the lung tissue density measured by CT-densitometry at6, 12, 24 months
- DLCO change from baseline at 6, 12, 24 months
- (and 7 more...)
|
0 |
All |
35 Years to 75 Years (Adult, Senior) |
NCT01849159 |
MSC-HYP-01
FMBA-FRCC-MSC-01 |
|
March 2014 |
December 2016 |
June 2017 |
May 8, 2013 |
January 9, 2018 |
|
- Federal Research Clinical Center of Federal Medical and Biological Agency of Russia
Moscow, Moscow Region, Russian Federation
|
| 22 |
NCT02815683 |
Recruiting |
Bronchoscopic EmphysemA Treatment in THE NetherLands |
|
|
Observational |
|
- University Medical Center Groningen
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quality of treatment
- Change from baseline in lungfunction at 5 years follow up after treatment.
- Change from baseline in exercise capacity at 5 years follow up after treatment.
- (and 3 more...)
|
500 |
All |
Child, Adult, Senior |
NCT02815683 |
BREATHE-NL |
BREATHE-NL |
September 2016 |
September 2021 |
September 2026 |
June 28, 2016 |
March 8, 2018 |
|
- University Medical Center Groningen
Groningen, Netherlands - Maastricht University Medical Center
Maastricht, Netherlands
|
| 23 |
NCT00269087 |
Completed |
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: fluticasone propionate/salmeterol combination DISKUS
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with any adverse events (AEs) and serious AEs (SAEs)
- Number of participants with abnormal (outliers from the normal range) hematology parameters
- Number of participants with abnormal (outliers from the normal range) clinical chemistry parameters
- (and 22 more...)
|
122 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00269087 |
SCO100648 |
|
January 2005 |
October 2006 |
October 2006 |
December 23, 2005 |
March 15, 2017 |
|
- GSK Investigational Site
Kodaira, Japan - GSK Investigational Site
Kyoto, Japan - GSK Investigational Site
Osaka, Japan - (and 2 more...)
|
| 24 |
NCT02935452 |
Not yet recruiting |
Implementing and Evaluating the Genie Tool in COPD |
|
- Behavioral: GENIE - social networking tool
|
Interventional |
Not Applicable |
- University of Southampton
- Solent NHS Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Compare and evaluate the health care utilisation
- Compare and evaluate burden of disease
- Compare and evaluate quality of life (mood)
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02935452 |
19175 |
GeCop |
November 2016 |
August 2017 |
August 2018 |
October 17, 2016 |
October 17, 2016 |
|
- University of Southampton
Southampton, United Kingdom
|
| 25 |
NCT02696564 |
Recruiting |
Losartan Effects on Emphysema Progression |
|
- Drug: Losartan
- Drug: Placebo
|
Interventional |
Phase 4 |
- Johns Hopkins University
- University of Pittsburgh
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
|
220 |
All |
40 Years and older (Adult, Senior) |
NCT02696564 |
U01HL128951 |
LEEP |
May 23, 2017 |
January 31, 2019 |
January 31, 2019 |
March 2, 2016 |
February 15, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Arizona
Tucson, Arizona, United States - University of California at San Diego
San Diego, California, United States - (and 14 more...)
|
| 26 |
NCT02877459 |
Active, not recruiting |
Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Serious Adverse Events
- Forced Expiratory Volume in one second (FEV1)
- Residual volume (RV)
- (and 5 more...)
|
14 |
All |
40 Years and older (Adult, Senior) |
NCT02877459 |
630-0019 |
STAGE |
November 2016 |
November 16, 2017 |
August 2018 |
August 24, 2016 |
April 9, 2018 |
|
- Ludwig-Boltzmann-Institut für COPD und Pneumologische Epidemiologie
Wien, Austria - Charité Campus Virchow Klinikum (CVK)
Berlin, Germany - Thoraxklinik am Universitäts klinikum Heidelberg
Heidelberg, Germany - University Medical Center Groningen
Groningen, Netherlands
|
| 27 |
NCT00534404 |
Completed
Has Results |
A Randomized Trial of Internet Access to Nicotine Patches |
- Smoking Cessation
- Tobacco Use Disorder
|
- Drug: Nicotine patches
- Behavioral: Telephone counseling
- Behavioral: iQuit Smoking website
|
Interventional |
Not Applicable |
- University of Michigan
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Self-reported 6-month Prolonged Abstinence From Smoking
- Self-reported 30-day Prolonged Abstinence at 9-month Follow up
- Self-reported 30-day Prolonged Abstinence at 3-month Follow up
|
2485 |
All |
18 Years and older (Adult, Senior) |
NCT00534404 |
511
R01HL086684-01 |
iQS |
March 2011 |
March 2014 |
March 2014 |
September 24, 2007 |
February 3, 2015 |
February 3, 2015 |
- University of Michigan
Ann Arbor, Michigan, United States
|
| 28 |
NCT00563641 |
Completed |
Very Early Surfactant and NCPAP for Premature Infants With RDS |
- Respiratory Distress Syndrome
- Pneumothorax/Pulmonary Intersticial Emphysema
- Chronic Lung Disease
|
- Other: Very early surfactant and bubble NCPAP
- Other: bubble NCPAP
|
Interventional |
Phase 3 |
- Colombian Neonatal Research Network
- Pontificia Universidad Javeriana
- Vanderbilt University School of Medicine
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Need for mechanical ventilation
- Neonatal mortality
- Air leak syndrome
- Oxygen dependency at 36 weeks post menstrual age
|
278 |
All |
27 Weeks to 31 Weeks (Child) |
NCT00563641 |
ColombianCNRNCPAP trial
Abbott Laboratories Grant |
CNRNCPAP |
January 2004 |
|
December 2006 |
November 26, 2007 |
November 26, 2007 |
|
- Department of Epidemiology and Biostatistics Pontificia Universidad Javeriana
Bogota, Cundinamarca, Colombia
|
| 29 |
NCT00000621 |
Completed |
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) |
- Emphysema
- Lung Diseases
- Lung Diseases, Obstructive
- Chronic Obstructive Pulmonary Disease
|
- Drug: all trans retinoic acid
- Drug: 13 cis retinoic acid
- Drug: placebo
|
Interventional |
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
All |
45 Years and older (Adult, Senior) |
NCT00000621 |
124 |
|
September 1999 |
December 2004 |
December 2004 |
October 28, 1999 |
January 16, 2008 |
|
|
| 30 |
NCT02382367 |
Completed |
Prevalence of Alpha-1 Antitrypsin Dysfunction in Pulmonary Emphysema |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of patient with alpha-1 antitrypsin dysfunction
- Determination of alpha-1 antitrypsin protein phenotype
- Molecular genotyping of gene coding alpha-1 antitrypsin
|
190 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02382367 |
2013.835 |
DysA |
December 2014 |
December 2015 |
December 2015 |
March 6, 2015 |
December 7, 2015 |
|
- Hôpital Louis Pradel - service de pneumologie
Bron, France
|
| 31 |
NCT02305160 |
Completed |
A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants |
- Respiratory Distress Syndrome
|
- Drug: Butantan
- Drug: Control
|
Interventional |
Phase 2
Phase 3 |
- University of Sao Paulo
- Ministry of Health, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mortality rate
- The incidence of adverse effects as: pneumothorax, pneumomediastinum, pulmonary interstitial emphysema, pulmonary hemorrhage and bronchopulmonary dysplasia (BPD).
|
327 |
All |
up to 24 Hours (Child) |
NCT02305160 |
012005B |
|
April 2005 |
May 2006 |
July 2007 |
December 2, 2014 |
December 2, 2014 |
|
- Hospital Esau de Matos
Vitoria da Conquista, BA, Brazil - Hospital Regional de Taguatinga
Brasilia, DF, Brazil - Hospital Materno Infantil
Goiania, GO, Brazil - (and 27 more...)
|
| 32 |
NCT00269126 |
Completed |
Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: fluticasone propionate/salmeterol combination DISKUS
- Drug: salmeterol xinafoate
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in pre-dose FEV1 at 4 weeks after starting medication of GW815SF 50/250µg
- Change in morning PEF
- Changes in pre-dose FVC, V50, V25
- (and 2 more...)
|
150 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00269126 |
SCO100646 |
|
February 2005 |
August 2005 |
August 2005 |
December 23, 2005 |
April 15, 2013 |
|
- GSK Investigational Site
Kyoto, Japan - GSK Investigational Site
|
| 33 |
NCT00243282 |
Completed |
Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life |
- Pulmonary Disease, Chronic Obstructive
|
- Behavioral: Relaxation Response (instruction, pocket practice card prov)
- Behavioral: Mindfulness training using model developed from UMass
|
Interventional |
Not Applicable |
- VA Office of Research and Development
- Samueli Institute for Information Biology
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary study outcomes are patients' self report of the severity of dyspnea and HRQOL. Baseline dyspnea will be quantified with the Baseline Dyspnea Index and Borg scale with regular measures of dyspnea using the Visual Analog Scale (VAS). HRQOL will be
- Functional limitation will be measured by the 6-minute walk test and followed with the baseline measure of post-exercise dyspnea level on the Borg scale. Other symptoms will be identified by the Memorial Symptom Assessment Scale (MSAS) and as part of the
|
120 |
All |
Child, Adult, Senior |
NCT00243282 |
S05-Shekelle0024
PCC 2005-081225 |
|
October 2005 |
|
October 2006 |
October 21, 2005 |
January 21, 2009 |
|
- Greater Los Angeles VA Healthcare System
Los Angeles, California, United States
|
| 34 |
NCT01744093 |
Active, not recruiting |
Doxycycline for COPD in HIV-Infected Patients |
- HIV
- Chronic Obstructive Pulmonary Disease (COPD)
- Emphysema
|
- Drug: Doxycycline
- Drug: Placebo (sugar pill)
|
Interventional |
Not Applicable |
- Weill Medical College of Cornell University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of participants with adverse events as a measure of safety and tolerability
- Measure of physiologic and biologic effects based on levels of MMP activity in epithelial lining fluid before and after study drug administration.
|
61 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01744093 |
1208012780 |
|
July 17, 2014 |
October 25, 2017 |
June 30, 2018 |
December 6, 2012 |
January 10, 2018 |
|
- GeneticMedicine
New York, New York, United States
|
| 35 |
NCT00613860 |
Unknown † |
Sequential Endoscopic Lung Volume Reduction |
|
- Device: Zephyr endobronchial valve
|
Interventional |
Phase 3 |
- Heidelberg University
- Humboldt-Universität zu Berlin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- FEV 1 6 Minute walk test
- Safety Symptom scores
|
30 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00613860 |
02/08 |
|
January 2008 |
December 2011 |
December 2011 |
February 13, 2008 |
April 27, 2011 |
|
- Charite, University of Berlin
Berlin, Germany - Thoraxklinik, University of Heidelberg
Heidelberg, Germany - Medical Center Nürnberg
Nürnberg, Germany
|
| 36 |
NCT01110200 |
Completed
Has Results |
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: ADVAIR DISKUS 250/50 mg BID
- Drug: SEREVENT 50 mcg BID
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred >21 Days Post-discharge/Physician's Office Visit for a COPD EX Requiring Treatment With Oral Corticosteroids (OCSs) or OCSs and Antibiotics (ABs)
- Number of Participants With the Indicated Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician's Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs
- Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician's Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs
- (and 2 more...)
|
639 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT01110200 |
113874 |
|
April 30, 2010 |
April 1, 2012 |
May 8, 2012 |
April 26, 2010 |
November 8, 2017 |
January 18, 2013 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Florence, Alabama, United States - (and 100 more...)
|
| 37 |
NCT00857038 |
Unknown † |
Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) |
- Chronic Obstructive Pulmonary Disease
- Inflammation
- Pulmonary Emphysema
|
- Drug: Doxycycline
- Drug: Placebo
|
Interventional |
Phase 4 |
- Medical Center Alkmaar
- Leiden University Medical Center
- University of Amsterdam
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- myeloperoxidase in induced sputum
- MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum.
- Lung function (FEV1)
- Symptom scores
|
30 |
All |
41 Years and older (Adult, Senior) |
NCT00857038 |
M07-046 |
|
April 2009 |
August 2009 |
January 2010 |
March 6, 2009 |
March 6, 2009 |
|
- Medical Center Alkmaar
Alkmaar, Noord-Holland, Netherlands
|
| 38 |
NCT02942134 |
Not yet recruiting |
Acute Dyspnea After Use of Non-invasive Ventilation in COPD and Emphysema (Deventilation Syndrome) |
- Obstructive Chronic Bronchitis
|
|
Observational |
|
- Felix JF Herth
- Heidelberg University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Incidence and severity of acute dyspnea after use of non-invasive Ventilation in COPD and emphysema
|
70 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02942134 |
S-484/2016 |
|
November 2016 |
October 2017 |
May 2018 |
October 21, 2016 |
October 21, 2016 |
|
|
| 39 |
NCT01969734 |
Completed |
Endobronchial Valves in Moderate COPD |
|
- Device: Zephyr endobronchial valve placement
|
Interventional |
Not Applicable |
- Sherwood Forest Hospitals NHS Foundation Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in residual volume
- Change in FEV1
- Change in vital capacity
- (and 7 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT01969734 |
SFH2 |
REMODEL |
March 2014 |
March 2015 |
March 2015 |
October 25, 2013 |
May 23, 2017 |
|
- Kings Mill Hospital
Sutton-in-Ashfield, Nottinghamshire, United Kingdom
|
| 40 |
NCT02179125 |
Recruiting |
Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Device: RePneu Lung Volume Reduction Coil System
|
Interventional |
Not Applicable |
- University Medical Center Groningen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in physical activity at 3 months.
- Change from baseline in patient reported outcomes of the treatment at 3 months follow up.
- Change from baseline in dynamic lung hyperinflation at 3 months follow up.
- (and 6 more...)
|
48 |
All |
Child, Adult, Senior |
NCT02179125 |
REACTION
NL49716.042.14 |
REACTION |
March 2015 |
December 2018 |
December 2018 |
July 1, 2014 |
June 27, 2017 |
|
- University Medical Center Groningen
Groningen, Netherlands - Royal Brompton Hospital & Imperial College
London, United Kingdom
|
| 41 |
NCT02633293 |
Enrolling by invitation |
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE |
- Pulmonary Hypertension
- Interstitial Lung Disease
- Combined Pulmonary Fibrosis and Emphysema
|
- Drug: Inhaled Treprostinil
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Peak 6-Minute Walk Distance (6MWD) from Baseline to the Week 48 Visit
- Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to the Week 48 Visit
- Change in Forced Expiratory Volume (FEV1) in One Second from Baseline to Week 48
- (and 4 more...)
|
266 |
All |
18 Years and older (Adult, Senior) |
NCT02633293 |
RIN-PH-202 |
|
September 2016 |
October 2020 |
October 2020 |
December 17, 2015 |
March 7, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - IMC-Diagnostic & Medical Clinic
Mobile, Alabama, United States - Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona, United States - (and 107 more...)
|
| 42 |
NCT02629432 |
Completed |
Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT |
- Chronic Obstructive Pulmonary Disease (COPD)
|
|
Observational |
|
- University Hospital Heidelberg
- Philipps University Marburg Medical Center
- Hannover Medical School
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sensitivity and specificity of MRI for the diagnosis of emphysema-predominant vs. airway-predominant COPD phenotype based on semi-quantitative visual image evaluation with CT as standard of reference
- number of completed examinations with diagnostic image quality to determine the achievable diagnostic quality of lung MRI in a multi-center setting
- agreement of visual and software-based phenotyping on MRI and CT (airway wall thickening, air trapping, emphysema, lung perfusion deficits)
- (and 2 more...)
|
602 |
All |
40 Years and older (Adult, Senior) |
NCT02629432 |
01GI0884 |
MR-COPD |
December 2013 |
July 2016 |
July 2016 |
December 14, 2015 |
May 11, 2017 |
|
- Universitätsklinikum, Diagnostische und Interventionelle Radiologie und Neuroradiologie
Essen, Germany - Universitätsklinikum Gießen und Marburg GmbH,Klinik für Diagnostische und Interventionelle Radiologie
Giessen, Germany - Universitätsmedizin Greifswald, Institut für Diagnostische Radiologie u. Neuroradiologie
Greifswald, Germany - (and 12 more...)
|
| 43 |
NCT01998724 |
Active, not recruiting |
Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Behavioral: Tai Chi
- Behavioral: Group Walking
|
Interventional |
Not Applicable |
- Beth Israel Deaconess Medical Center
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Feasibility of tai chi intervention
- Change from baseline - Disease specific quality of life
- Change from baseline - Exercise capacity
- (and 4 more...)
|
90 |
All |
40 Years and older (Adult, Senior) |
NCT01998724 |
2012P000220
R01AT006358 |
LEAP |
August 2012 |
June 2018 |
June 2018 |
December 2, 2013 |
January 8, 2018 |
|
- VA Healthcare System
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 44 |
NCT01014442 |
Completed
Has Results |
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients |
|
- Drug: mycophenolate mofetil
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4
- Cmax of MPA, MPAG and AcMPAG at Day 8
- Cmax of MPA, MPAG and AcMPAG at Day 20
- (and 51 more...)
|
68 |
All |
18 Years and older (Adult, Senior) |
NCT01014442 |
ML22608
2009-012231-15 |
|
January 2010 |
June 2012 |
June 2012 |
November 17, 2009 |
February 10, 2017 |
February 10, 2017 |
- Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School
Hannover, Germany
|
| 45 |
NCT01020344 |
Completed |
Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary Disease |
- Chronic Obstructive Pulmonary Disease
|
- Procedure: Lung volume reduction surgery
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1. Systemic inflammation 2. Vascular function
- 1. Oxidative stress 2. Blood pressure 3. Physical Activity 4. Lung function 5. Hypoxemia
|
30 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT01020344 |
COPD-CVD2 |
|
November 2009 |
October 2014 |
October 2014 |
November 25, 2009 |
October 16, 2014 |
|
- Pulmonary Division, University Hospital of Zurich
Zurich, Switzerland
|
| 46 |
NCT02266316 |
Unknown † |
Use of an Air Warming Mask for Exercise in Patients With COPD V1.0 |
- Chronic Obstructive Pulmonary Disease
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- The primary outcome measure for the study is the difference between forced expiratory volume in one second (FEV1) in litres per second before and after a 6 minute walk.
|
24 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02266316 |
WARM/COPD/1112 |
|
March 2012 |
July 2015 |
July 2015 |
October 17, 2014 |
October 17, 2014 |
|
- University of Worcester
Worcester, Worcestershire, United Kingdom
|
| 47 |
NCT00626522 |
Completed
Has Results |
Aclidinium/Formoterol Fixed Combination Dose Finding Study |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Drug: Aclidinium bromide and formoterol
- Drug: Aclidinium bromide and formoterol placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr
- Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1)
- Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
- (and 2 more...)
|
808 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00626522 |
M/273FO/23
2007-004435-30 |
|
February 2008 |
November 2008 |
November 2008 |
February 29, 2008 |
November 16, 2016 |
August 8, 2016 |
- Research Site
Taichung, Australia - Research Site
Taipei, Australia - Research Site
Moscow, Czech Republic - (and 8 more...)
|
| 48 |
NCT02917915 |
Recruiting |
The CaNadian Standardized Pulmonary Rehabilitation Efficacy Trial |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Other: Canadian Standardized PR
- Other: Traditional PR
|
Interventional |
Not Applicable |
- University of Alberta
- McGill University
- University of Toronto
- Université de Sherbrooke
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Physical activity assessed as steps per day as evaluated by Fitbit and self-report
- Patient adherence to exacerbation action plan
- Medication adherence assessed by pharmacy refill records
|
200 |
All |
30 Years and older (Adult, Senior) |
NCT02917915 |
Pro00066560 |
CoNSPiRE |
January 2017 |
November 2018 |
November 2018 |
September 28, 2016 |
September 8, 2017 |
|
- G. F. MacDonald Centre for Lung Health
Edmonton, Alberta, Canada
|
| 49 |
NCT01235481 |
Completed |
Validation of an Exercise DVD for Maintenance After Pulmonary Rehabilitation. |
|
- Device: Exercise DVD
- Behavioral: Usual Care
|
Interventional |
Phase 3 |
- Nova Scotia Health Authority
- Capital Health, Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- 6MWD
- disease-specific quality of life (CRQ)
- exercise compliance
- (and 2 more...)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT01235481 |
CDHA-RS/2011-159 |
|
December 2010 |
June 2014 |
June 2014 |
November 5, 2010 |
May 13, 2015 |
|
- QEII Health Sciences Centre
Halifax, Nova Scotia, Canada - Cobequid Community Health Centre
Lower Sackville, Nova Scotia, Canada
|
| 50 |
NCT00175565 |
Completed |
Inhaled Steroid Reduces Systemic Inflammation in COPD |
- Chronic Obstructive Pulmonary Disease
- Emphysema
- Chronic Bronchitis
|
- Drug: inhaled fluticasone 500 mcg b.i.d.
|
Interventional |
Phase 4 |
- University of British Columbia
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change in serum C-reactive protein (CRP) levels
- Change in serum interleukin-6 and monocyte chemoattractant protein-1 levels
|
50 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00175565 |
4027 |
|
January 2002 |
|
July 2003 |
September 15, 2005 |
July 28, 2010 |
|
- University of Alberta
Edmonton, Alberta, Canada - University of British Columbia
Vancouver, British Columbia, Canada
|
Create an RSS feed from your search for:
Download the search results for: